Effect of acarbose on the need for between-meal snacking in patients with type 1 diabetes: A placebo-controlled, double-blind, cross-over study

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 11, Issue 3, 1998, Pages 169-174

  Frank, M ^a,b   Koglmeier J ^a   Sneige, N ^a   Alawi, H ^a  

^a Ev Fliedner Krankenhaus   (Germany)

^b Ev Fliedner Krankenhaus   (Germany)

Author keywords

Acarbose; Diet; Lifestyle; Snacking; Type 1 diabetes

Indexed keywords

ACARBOSE; GLUCOSE; INSULIN;

ADULT; ARTICLE; BLOOD SAMPLING; CARBOHYDRATE INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0031769004     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in IDDM. N. Engl. J. Med. 329: 977-986, 1993.
2. Janka H.U., Balletsofer B., Becker A. et al.: Das metabolische Syndrom als potenter Risikofaktor für frühzeitigen Tod bei Typ-11-Diabetikern. Die Schwabinger Studie II - Untersuchungen nach 9 Jahren. Diab. Stoffw. 1: 2-7, 1992.
3. Kuusisto J., Mykkänen L., Pyöräla K., Laakso M.: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43: 960-967, 1994.
4. Truscheit E., Hillebrand I., Junge B., Müller L., Puls W., Schmidt D.: Microbial alpha-glucosidase inhibitors: chemistry, biochemistry and therapeutic potential. Prog. Clin. Biochem. Med. 7: 17-99, 1988.
5. Hillebrand I., Boehme K., Frank G., Fink H., Berchthold P.: The effects of the alpha-glucosidase inhibitor BAY G 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin and triglyceride levels in man. Res. Exp. Med. 175: 81-86, 1979.
6. Puls W., Bischoff H., Schutt H.: Pharmacology of amylase- and glucosidase-inhibitors. In: Creutzfeldt W., Fölsch U.R. (Eds), Delaying absorption as a therapeutic principle in metabolic diseases. Thieme Verlag, Stuttgart, pp. 70-76, 1983.
7. Hollander P., Coniff R.F.: Two multicenter, double-blind, placebo-controlled studies of efficacy and safety of acarbose treatment of type 1 diabetes. Diabetes (Suppl. 1): 307A, 1991. (Astract).
8. Escobar-Jimenez F., de Leiva A., Pinon F., Soler J., Tebar J., Saacho M.A., Herrera-Pombo J.L., Pallardo L.F., Vazquez J.A., de la Calle H., et al.: Eficacia clinica y tolerancia de la acarbosa en el tratamiento de pacientes diabeticos dependentes da la insulina (tipo 1). Med. Clin. (Barc.) 100: 488-491, 1993.
9. Hoffmann J., Spengler M.: Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 17: 561-566, 1994.
10. Braun D., Schönherr U., Mitzkat H.J.: Efficacy of acarbose monotherapy in patients with type 2 diabetes: a double-blind study conducted in general practice. Endocrinol. Metab. 4: 275-280, 1996.
11. May C.: Wirksamkeit und Verträglichkeit von einschleichend dosierter Acarbose bei Patienten mit nichtinsulinpflichtigem Diabetes mellitus (Type-II-Diabetes) unter Sulfonylharnstofftherapie. Diab. Stoffw. 4: 3-8, 1995.
12. Hoffmann J., Spengler M.: Efficacy of 24-week monotherapy with acarbose, metformin or placebo in NIDDM patients with dietary failure. Diabetologia 39 (Suppl. 1): 230A, 1996. (Abstract).
13. Lindström J., Tuomilehto J., Spengler M.: The effect of acarbose on dietary nutrient intake and metabolic control in NIDDM patients. Diabetologia 39 (Suppl. 1): 195A, 1996. (Abstract).
14. Rodger N.W., Chiasson J.-L., Josse R.G., Hunt J.A., Palmason C., Ross S.A., Ryan E.A., Tan M.H., Wolever T.M.: Clinical experience with acarbose: results of a Canadian multicentre study. Clin. Invest. Med. 18: 318-324, 1995.